Risk Communication Advisory Committee

Purpose

The Committee advises the Commissioner and designees on strategies and programs designed to communicate with the public about the risks and benefits of FDA-regulated products so as to facilitate optimal use of these products. The Committee also reviews and evaluates research relevant to such communication to the public by both FDA and other entities. It also facilitates interactively sharing risk and benefit information with the public to enable people to make informed independent judgments about use of FDA-regulated products.

Committee Membership

The committee shall consist of a core of 15 voting members including the Chair. Members will be appointed as Special Government Employees except for members representing industry interests. Members and the chair are selected by the Commissioner or designee from among authorities knowledgeable in the fields of risk communication, social marketing, health literacy, cultural competency, journalism, bioethics, and other relevant behavioral and social sciences. Some members will be selected to provide experiential insight on the communication needs of the various groups who use FDA-regulated products. The latter may include patients and patients' family members, health professionals, communicators in health, medicine and science, and persons affiliated with consumer, specific disease, or patient safety advocacy groups. Depending on the meeting topic(s), at least one nonvoting member identified with relevant industry interests may be invited from existing members of other FDA Advisory Committees.

 

Contact Information

Lee L. Zwanziger, Designated Federal Official
Office of Commissioner
5600 Fisher Lane, Rm. 15-22
Rockville, MD 20857
email: Lee.Zwanziger@fda.hhs.gov
phone:  301-827-2895

FDA Advisory Committee Information Line
1-800-741-8138
(301-443-0572 in the Washington, DC, area)
code 8732112560
Please call the Information Line for up-to-date information on meetings